Azilsartan Circadian and Sleep Pressure
Hypertension

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension
Eligibility Criteria
Inclusion Criteria:
- Grade I or II essential hypertension
- The sitting systolic blood pressure is in term of 140-179 mmHg, or sitting diastolic blood pressure is in term of 90-109 mmHg at the both two time points at the beginning of the observation period and at the beginning of a treatment period (Week0)
- 20 years old or older at the time of the informed consent
- Able to give written informed consent before participating in the research
- Therapeutic category during the observation period: Ambulatory
Exclusion Criteria:
- Secondary hypertension, grade III hypertension (sitting systolic blood pressure greater than or equal to 180 mmHg or sitting diastolic blood pressure greater than or equal to 110 mmHg), malignant hypertension
- More than 2 kinds of antihypertensive agents for treatment on the hypertension
- History of taking following medicines within 2 weeks before start of the observation period.
When subject with taking any of the following medicine at the time of informed consent is included, stop to take the medicine for determined period after the informed consent.
I. Antihypertensive agents II. Antianginal agents III. Antiarrhythmic agents (except single time use of the lidocaine hydrochloride formulation for anesthesia) IV. Digitalis products
- Less than 130 mmHg of mean 24-hour systolic blood pressure and less than 80 mmHg of mean 24-hour diastolic blood pressure at the start of the observation period.
- History of following circulatory-related diseases or symptoms within 24 weeks before start of the observation period.
I. Cardiac disease: Myocardial infarction, coronary artery revascularization II. Cerebrovascular-disease: cerebral infarction, cerebral hemorrhage, transient ischemic attack III. Progressive hypertensive retinopathy: hemorrhage, exudation, or papilledema
- History or complication with the following circulatory-related diseases; Valvular stenosis, atrial fibrillation, pharmacotherapy-required angina, congestion heart failure, or cardiac arrhythmia, or arteriosclerosis obliterans with symptoms of intermittent claudication et al
- Day / night reversal
- History of hypersensitivity or allergy to Azilsartan, Amlodipine, or related drugs
- Participant in any other clinical research
- Pregnant, possible to being pregnant, or lactating woman
- Mal-control of blood pressure during informed consent to taking antihypertensive agent
- Any those the investigator or other researchers consider as unsuitable
Sites / Locations
- Jyuzen General Hospital
- Junn Clinic
- Seikei-kai New Tokyo Hospital
- Sanshukai Doi Internal Medicine Clinic
- Junshinkai Nakamura Cardiovascular Clinic
- Osaki Clinic
- Osamura Medical Clinic
- Hoshi General Hospital
- Zensyukai Hospital
- Hakushoukai Sano Hospital
- Jiseikai Higashiasahikawa Hospital
- Koushinkai Shintomi Naika Clinic
- Aoki Clinic
- Houwakai Sapporo Hospital
- Mitani Clinic
- Shinkotoni Family Clinic
- Shoureikan Shinsapporo Seiryou Hospital
- Tomakomai City Hospital
- Hukuyo naika clinic
- Asunaro medical Clinic
- Keiseikai Gohshi Hospital
- Keijukai Itabashi Clinic
- Kamata medical Clinic
- Koyokai Hanamure Hospital
- Izumi General Medical Center
- Iroden Clinic
- Nagasu Clinic
- Himawari-kai Kanagawa Himawari Clinic
- Kawasaki Saiwai Clinic
- Wakoukai Kawasaki Rinko General Hospital
- Hakuai Clinic
- Kaneshiro Diabetes Clinic
- Yamamoto Clinic
- Tsuruma Kaneshiro Diabetes Clinic
- Furuie Clinic
- Minamisawa Clinic
- Shintoukai Yokohama Minoru Clinic
- Shuyu-kai Kikuchi Clinic
- Tani Clinic
- Higashikatsuyama Nakazawa Naika Allergy Internal Medicine
- Shinden Higashi Clinic
- Meiwakai Izaki Clinic
- Shoninkai Shonin Hospital
- Hirano Doujinkai Tsuyama Daiichi Hospital
- Taira Hospital
- Tenjin Tanaka Internal Medicine Clinic
- Enomoto Clinic
- Kazo Minami Clinic
- Asukurepiosu Enomoto Clinic
- Shibuya Clinic
- Genkikai Wakasa Clinic
- JA Shizuoka Kohseiren Enshu Hospital
- Shimoda Medical Center
- Jichi Medical University Hospital
- DIC Utsunomiya Central Clinic
- Nippori Clinic
- Eireikai Niwa Family Clinic
- Keiyu Clinic
- Nihonbashikabutocho Nakajima Clinic
- Tokyo Center Clinic
- Taiseikai Seikoudou Clinic
- Hirookai Kanbara Clinic
- Ono Medical Clinic
- Sawai Medical Clinic
- Shinsei-kai Kameido Ekimae Ckinic
- Shinseikai Kameido Minami-guchi Clinic
- Kamada Clinic
- Mitaka Health Care Clinic
- Murenosato Clinic
- Shirayurikai Swing Bldg Nozaki Clinic
- Kenkoukan Suzuki Clinic
- Keichikai Shimokitazawa Tomo Clinic
- Ishinkai Oda Clinic
- Ryousyukai Kanauchi Medical Clinic
- Shingakai MaO Clinic
- Keiseikai Otsuka Kita-guchi Clinic
- Fujino Clinic
- Hirokai Higashikatsura Medical Clinic
- Hakataeki-higashi Clinic
- Ogata Medical Clinic
- Soejima Naika Clinic
- Inoue Neurology Clinic
- Oda medical Clinic
- Aiseikai PS Clinic
- Kosei-kai Nijigaoka Hospital
- Seizenkai Okayama Saidaiji Hospital
- Yasuda Clinic
- AMC Nishiumeda Clinic
- Kouseikai Chimori Medical Clinic
- H&Y Akimoto Naika Clinic
- Shiseidou Tomita Hospital
- Takahashi Clinic
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Azilsartan
Amlodipine
Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks